USPTO 2015–2025 USPTO PatentsView US Corporation

PURDUE PHARMACEUTICALS L.P.

USPTO PatentsView assignee record — 73 granted patents across 8 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

73
Total patents granted
8
CPC technology areas
22.4
Avg claims per patent
-74%
5-year filing velocity

Portfolio overview

PURDUE PHARMACEUTICALS L.P. has been granted 73 US utility patents between 2015 and 2025, placing PURDUE PHARMACEUTICALS L.P. at rank #4,783 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, PURDUE PHARMACEUTICALS L.P. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 51.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 15 grants, compared with 58 in the 2015–2019 window — a -74% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. PURDUE PHARMACEUTICALS L.P.'s 22.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark PURDUE PHARMACEUTICALS L.P. against peers pursuing similar technology classes.

How does PURDUE compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows PURDUE holds 73 patents — placing it at rank #4,783 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

05101520 2015201620172018201920202022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
PURDUE PHARMACEUTICALS L.P. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 10 13.7%
2016 17 23.3%
2017 14 19.2%
2018 14 19.2%
2019 3 4.1%
2020 2 2.7%
2022 5 6.8%
2023 1 1.4%
2024 4 5.5%
2025 3 4.1%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining

Where it ranks

Overall rank by patents

#4,783

Across all tracked assignees

Innovation Score

51.6 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does PURDUE PHARMACEUTICALS L.P. hold?
PURDUE PHARMACEUTICALS L.P. holds 73 US granted patents filed between 2015 and 2025, spanning 8 technology areas.
What is PURDUE PHARMACEUTICALS L.P.'s Innovation Score?
PURDUE PHARMACEUTICALS L.P. has an Innovation Score of 51.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does PURDUE PHARMACEUTICALS L.P. focus on?
PURDUE PHARMACEUTICALS L.P.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 69 patents. The company has filed patents in 8 CPC subclasses total.
Is PURDUE PHARMACEUTICALS L.P.'s patent filing rate increasing or decreasing?
PURDUE PHARMACEUTICALS L.P.'s recent filing velocity is -74% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for PURDUE PHARMACEUTICALS L.P.'s patents?
PURDUE PHARMACEUTICALS L.P.'s patents average 22.4 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the PURDUE PHARMACEUTICALS L.P. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope